TurtleTree
Singapore startup making cow-free lactoferrin and dairy proteins via precision fermentation.
On the record
Checkpoint: Whether real product revenue ships through the Novonesis channel
The call
TurtleTree holds a genuine regulatory head start on lactoferrin but has no revenue, a shrunken team, and now depends on Novonesis for both manufacturing and its own survival.
TurtleTree uses fermentation to create lactoferrin, a natural protein found in milk, without raising animals. The company got U.S. government approval first in 2025 and has a deal with Novonesis to make and sell the product, which is hard for others to copy right now because of those regulatory approvals and the partnership. The real problem is that TurtleTree has almost no money, no revenue yet, and key people have left the company, so it may not survive long enough to actually sell anything, and Novonesis could end up buying it for cheap or simply become the only real owner of the business.
Why
01
AI pressure: None apparent. AI tools speed up protein engineering research industry-wide but no AI product competes with TurtleTree's lactoferrin directly. Could AI do the core job? Unlikely.
02
Bigger players: Novonesis. Novonesis is TurtleTree's exclusive manufacturing partner but also the bigger player that could commercialize lactoferrin alone or simply buy TurtleTree out. Could a giant copy it? Probably.
03
What protects it. First FDA No Questions Letter for precision-fermented lactoferrin gives TurtleTree a regulatory head start rivals do not yet have.
What would change this call
TurtleTree closes a disclosed Series B or bridge round within 2-3 quarters. Clean raise signals recovery; bridge or no raise signals continued financial distress.
Confirmed shipped, non-vendor-claimed revenue through Novonesis or Strive channels. Would show TurtleTree can commercialize its FDA-cleared lactoferrin despite thin staffing.
All G Foods or De Novo Foodlabs secures its own FDA clearance for lactoferrin. Would erode TurtleTree's first-mover regulatory moat.
Confirmed shipped, non-vendor-claimed revenue through Novonesis or Strive channels. Would show TurtleTree can commercialize its FDA-cleared lactoferrin despite thin staffing.
All G Foods or De Novo Foodlabs secures its own FDA clearance for lactoferrin. Would erode TurtleTree's first-mover regulatory moat.
Key numbers
- Zero reported revenue in 2023
- Losses widened 43% year over year
- FDA No Questions Letter for LF+ lactoferrin
Named risks
- Zero reported 2023 revenue with losses widening 43%, cash runway highly uncertain.
- Skeleton team after multiple 2024-2025 layoff rounds may struggle to execute Novonesis scale-up.
- Founder and C-suite exodus (Max Rye, CMO, CFO, CIO, Director of Scientific Affairs) weakens leadership continuity.
- Novonesis now controls manufacturing and commercialization access, creating dependency and possible acquisition pressure.
- Multiple funded rivals (All G Foods, De Novo Foodlabs) chasing same lactoferrin molecule could erode first-mover edge.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Novonesis | contesting | Became TurtleTree's sole manufacturing and commercialization gatekeeper via exclusive deal, 2026-07-08 |
| All G Foods | losing to | Directly targets same lactoferrin molecule with active funding as of 2026-02-27 |
| De Novo Foodlabs | losing to | Competing lactoferrin developer named alongside TurtleTree, 2026-02-27 |
| Perfect Day | losing to | Most commercially mature precision-fermentation dairy peer, existing ADM partnership, per 2025-02-06 review |
Questions people ask
- Is TurtleTree profitable in 2026?
- No. TurtleTree reported zero revenue in 2023 and losses widened 43% that year, per Green Queen's January 14, 2025 report citing DealStreetAsia. No subsequent public financials show a turnaround, and the company was still seeking a $15M pre-Series B round as of late 2024.
- Did TurtleTree have layoffs?
- Yes. TurtleTree underwent multiple rounds of layoffs between mid-2024 and January 2025, shrinking to a skeleton team, per Green Queen (2025-01-14). C-suite departures included co-founder Max Rye, the CMO, CFO, Chief Innovation Officer, and Director of Scientific Affairs.
- Who owns TurtleTree?
- TurtleTree Labs is privately held and Singapore-headquartered, founded 2019 by CEO Fengru Lin. Backers include VERSO Capital (2021 Series A tranche) and, as of July 8, 2026, an undisclosed minor equity stake from Novonesis and 21Catalyst Ventures alongside an exclusive manufacturing deal.
- Could AI replace TurtleTree's business?
- Not directly. TurtleTree's value sits in wet-lab strain engineering, fermentation, and FDA regulatory clearance, physical work AI can't substitute. AI could speed rivals' protein design, but TurtleTree's May 20, 2025 FDA No Questions letter for lactoferrin is a slow-to-replicate regulatory moat.
- Who is TurtleTree's biggest competitor?
- All G Foods and De Novo Foodlabs directly target the same lactoferrin molecule as TurtleTree, per FoodNavigator (2026-02-27). Perfect Day is the most commercially mature precision-fermentation dairy peer overall, with existing ADM partnerships, though TurtleTree holds first FDA clearance for lactoferrin specifically.
- What deal is TurtleTree relying on for revenue?
- An exclusive manufacturing and commercialization agreement with Novonesis for its LF+ lactoferrin in early-life nutrition and supplements, signed and announced July 8-9, 2026, giving TurtleTree access to established scale-up capacity it lacks internally.
Timeline
- 2026-07-09Novonesis press release confirms it will manufacture and commercialize TurtleTree's LF+
- 2026-07-08Novonesis signs exclusive LF+ deal, joins 21Catalyst Ventures in minor undisclosed investment
- 2026-02-27Sector-wide funding surge reported across precision-fermented dairy startups
- 2025-07TurtleTree forms Scientific Advisory Board
- 2025-05-20TurtleTree secures FDA No Questions letter for precision-fermented lactoferrin LF+
- 2025-01-14Major layoffs and C-suite exodus disclosed amid fundraising struggles
- 2024-11-20Partnership with MAD Foods announced for RTD coffee line targeting mid-2025 launch
- 2024-06-26Strategic partnership with Strive Nutrition announced for immunity beverage and protein powder
- 2021-11-01TurtleTree raises $30M Series A tranche, cumulative funding tops $40M
- 2020-12-17TurtleTree raises $6.2M pre-Series A funding
Revision history
25 July 2026
First assessed. Losing its protection. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Our Technology
- Animal-Free Lactoferrin Maker TurtleTree Shrinks Staff Amid Fundraising Woes (2025-01-14)
- TurtleTree Raises US$30 Million in First Tranche of Series A Funding (2021-11-01)
- SignalHire Company Profile
- TurtleTree Secures FDA 'No Questions' Letter (2025-05-20)
- Mad Foods and TurtleTree introduce RTD coffee beverage line (2024-11-21)
- TurtleTree Announces Strategic Partnership with Strive (2024-06-26)
- TurtleTree Announces Formal Partnership with MAD Foods (2024-11-20)
- Novonesis Invests in TurtleTree to Scale Up Cow-Free Lactoferrin for Early Nutrition (2026-07-08)
- TurtleTree, Novonesis partner on precision-fermented lactoferrin (2026-07-08)
- TurtleTree Blog
- Precision Fermentation: The Path to Animal-Identical Dairy Solutions (2025-02-06)